|
|
Article: Vicuron's dalbavacin granted priority review.(Vicuron Pharmaceuticals Inc.'s antibiotic for complicated skin and soft tissue infections)(Brief Article)
- Article from:
- Pharma Marketletter
- Article date:
- March 7, 2005
CopyrightCOPYRIGHT 2005 Marketletter Publications Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Shares in Vicuron Pharmaceuticals closed up 3.9% on February 24, as investors welcomed the news that the US group's New Drug Application for its novel, once-weekly antibiotic dalbavacin has been granted priority review status by the US Food and Drug Administration.
The agent is under evaluation for the treatment of complicated skin and soft tissue infections, including the notoriously difficult-to-treat methicillin-resistant Staphylococcus aureus, and industry observers have forecast peak annual ...